View more job listings or post a job
Genentech Scientist, DMPK
Pliant Therapeutics, Inc. Associate Director/ Director, Formulation Development
AbVision Inc. Research Scientist (Immunology/Cell Biology, all levels available)
Regulus Therapeutics Senior Research Associate/Scientist, Drug Metabolism and Pharmacokinetics
Aligos Therapeutics Principal Research Scientist, DMPK
PPD, Inc. Senior Scientist - Quality Control - HPLC - Dissolution - Method Validation
Aligos Therapeutics Director DMPK
Genentech Senior Scientific Researcher, DMPK
Genentech Scientist/Sr. Scientist Small Molecule - In Vitro DMPK
Post a job


Drug-Drug Interactions: Update on Risk Assessment, Clinical Evaluation, and Regulatory Requirements

Speakers: Simon Wong, Jing Wang, Jialin Mao, Kari Morrissey (Genentech); Jingjing Yu (UW); Xinning Yang (FDA); Ilaria Badagnani (Theravance Biopharma); Yurong Lai (Gilead)
Organizers: Simon Wong (Genentech), Snow Ge (Nektar)
Date: 2018-10-16
Time: 8:45-17:00 Pacific Time
Registration fee (USD): Regular: $195; Academic: $125; For unemployed or students: $30; For vendor-show rep: $35; For major-sponsor rep (incl lunch): $0
Location: SF Bay Area: Foster City Crowne Plaza
Major Sponsor: (2)Catalent Pharma Solutions; WuXi AppTec
Vendor show vendors registered to date: (22)Absorption Systems; BioDuro; BioreclamationIVT; Concept Life Sciences; Corning; Cyprotex; Cytovier; Envigo; Hurel Corp; ICON PLC; Intertek; KCAS Bioanalytical & Biomarker Services; Lonza; MicroConstants; Q2 Solutions; Quintara; Quotient Sciences; Sekisui XenoTech, LLC; Seventh Wave; Simulations Plus, Inc.; SOLVO Biotechnology; WORLDWIDE CLINICAL TRIALS
Registration deadline:2018-10-14  (it will close sooner if the seating cap is reached)

About the Topic

The potential for clinical drug-drug interactions (DDIs) continues to be of key liability for the development of new medicines.  This comprehensive workshop will review techniques and strategy to assess the potential for DDI's from early discovery to clinical development. In addition, clinical case studies will be explored highlighting interactions with regulatory authorities and accompanying strategies to understand and mitigate risk and expedite compound advancement.

Specific topics to be covered: 
  • Assessment of enzyme-based DDI's (induction/inhibition) and reaction phenotyping
  • Large molecule therapeutic protein interactions with small molecules
  • Recent strategies to utilize physiologically-based modeling for risk assessment
  • Update on transporter-mediated DDI's and clinical assessment
  • Design and interpretation of clinical DDI studies
  • Clinically relevant biomarkers for the assessment of transporter-mediated DDI's
  • Update and commentary on recent (2017) FDA draft guidance for DDI's


Workshop Agenda

8:45-8:50   PBSS Welcome - Simon Wong (Genentech)

8:50-9:25   1. Introduction and DDI Basics on Inhibition, Induction and Reaction Phenotyping - Simon Wong (Genentech)

9:25–10:00   2. Assessment of Therapeutic Protein Drug-Drug Interactions with Small Molecules - Jing Wang (Genentech)

10:00-10:10   Major Sponsor Presentation - TBD

10:10-10:35   Break & Vendor Show  

10:35-11:20   3. Physiologically-Based Modelling and DDI Risk Assessment - Jialin Mao (Genentech)

11:20–12:00   4. Design and Interpretation of Clinical DDI Studies - Kari Morrissey  (Genentech)

12:00-1:00   Lunch   

1:00–1:45   5. What Can Be Learned from Recent NDAs? Key Findings on Drug Interactions for Drugs Approved by the FDA - Jingjing Yu (University of Washington)

1:45–2:30   6. Update of DDI Draft Guidance - Xinning Yang (FDA)

2:30-2:40   Major Sponsor Presentation - TBD

2:40-3:00   Break & Vendor Show  

3:00-3:45   7. Transporter-mediated DDIs – What’s new in 2017 FDA draft guidance and industry application and risk assessment - Ilaria Badagnani (Theravance Biopharma)

4:00-4:45   8. Clinical Biomarkers for Transporter Mediated DDI - Yurong Lai (Gilead)

4:45-5:15   Panel Discussion - All

2019-07-26, Generating Efficacious Enzyme Therapeutics based on Knowledge Learned From Biocatalytic Pharmaceutical Manufacture
2019-09-13, Biotransformation and Disposition of Larger Molecules: Peptides, Nucleotides, Proteins, mAbs, and ADCs
2019-10-03, Small-Molecule Bioanalytical Method Validation & Regulated Bioanalysis: Fundamentals, the New FDA Guidance and Regulatory Trends
2019-10-18, Physiologically Based Pharmacokinetic (PBPK) Modeling: Fundamentals, Regulatory Guidance & Applications
2019-11-12, Antibody Drug Discovery and Development: Hit Generation, Engineering, Cell-line Development, IND enabling studies, and Biosimilars
2019-12-10, In vitro Diagnostics and Precision Medicine
2020-02-11, Drug-Device Combination
┬ęPharmaceutical & BioScience Society, International; Last Modified: 6/26/2019; Visited: 1002; Admin Logon
Ads (in random order)
Submit a Text Ad
($250 for 2 months)

Pacific BioLabs CRO in Bay Area - PK, toxicology, biocompatibility, analytical chemistry, immunogenicity, biomarker analysis, stability studies, sterility, endotoxin
Hypha Discovery mg-g scale synthesis/purification of CYP/non-CYP metabolites including glucuronides. Plus NEW PolyCYPs kits for in-house synthesis of CYP metabolites.
Immunomind Scientific Consulting - Protocol Development, Data Analysis, Lab Guidance, Tech Transfer - Meeting your project goals at a moment's notice.
Submit a Text Ad